The Patent Finder

Heparegenix GmbH

7 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2038
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,731,968) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,858,927) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (US 11,912,701) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

PatentTitleStatus Expires Confidence
US 11,040,027Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,264,158Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,858,927Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,731,968Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,912,701Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,466,8263-Benzoyl-1H-pyrrolo[2,3-b]pyridine Derivatives as MKK4 Inhibitors for Treating Liver Diseases
In force
 · Medium confidence
In forceMedium confidence
US 12,643,895Heteroaryl-Substituted Pyrazolo-Pyridine Protein Kinase Inhibitors for Promoting Liver Regeneration or Reducing or Preventing Hepatocyte Death
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited